PLSH PANACEA LIFE SCIENCES HOLDINGS, INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1552189 · Fiscal year ends 12/31
Financial factors as of 2023-03-31 (2023Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.7%
TTM net income YoY-3.7%
TTM EPS YoY-14.6%
Revenue 3-yr CAGR19.2%
Net income 3-yr CAGR—
Margins
Gross margin28.4%
Operating margin-288.0%
Net margin-443.5%
FCF margin-137.5%
EBITDA margin-196.4%
Returns
ROE-4,290.8%
ROA-39.8%
ROIC (approx.)-3,336.3%
Asset turnover0.09x
Leverage & solvency
Liabilities / assets120.5%
Debt / equity—
Current ratio0.37x
Interest coverage-2.75x
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio-28.7%
Payout ratio—
Capex / revenue13.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.38M | $1.63M |
| Cost of revenue | $1.26M | $1.23M |
| Gross profit | $1.12M | $396,470 |
| SG&A expense | $1.46M | $1.09M |
| Operating income | -$5.55M | -$5.65M |
| Interest expense | $1.56M | $2.05M |
| Pretax income | -$8.02M | -$9.14M |
| Net income | -$8.02M | -$9.14M |
| EBITDA | -$3.83M | -$3.98M |
| EPS (basic) | -0.48 | -0.62 |
| EPS (diluted) | -0.48 | -0.62 |
| Weighted avg. shares (diluted) | 16.63M | 14.86M |
| Balance sheet | ||
| Cash & equivalents | $100,922 | $6,951 |
| Short-term investments | $14,933 | $1.11M |
| Receivables | $263,970 | $206,127 |
| Inventory | $4.01M | $4.45M |
| Current assets | $4.66M | $6.38M |
| PP&E, net | $6.45M | $7.68M |
| Goodwill | $3.01M | $2.19M |
| Intangibles | $3.01M | $2.19M |
| Total assets | $17.98M | $19.49M |
| Current liabilities | $19.45M | $15.07M |
| Total liabilities | $26.27M | $21.63M |
| Shareholders' equity | -$8.29M | -$2.14M |
| Shares outstanding | 17.65M | 14.97M |
| Cash flow statement | ||
| Operating cash flow | -$1.52M | -$2.40M |
| Capital expenditure | $65,322 | $243,804 |
| Free cash flow | -$1.59M | -$2.64M |
| Investing cash flow | -$65,322 | -$196,972 |
| Financing cash flow | $1.68M | $2.58M |
| Depreciation & amortization | $1.71M | $1.67M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.